An AstraZeneca Pharmaceuticals PLC subsidiary faces a lawsuit from a former director who said she was subjected to sexist treatment from male colleagues and retaliation after filing a report with HR ...

Shares of AstraZeneca PLC AZN inched up 0.28% to £105.68 Thursday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100 Index UKX rising 0.12% to 8,311.76.

We recently published a list of Jim Cramer’s Lightning Rounds: 12 Stocks Under the Spotlight. In this article, we are going ...

AstraZeneca and Merck report Lynparza's significant survival benefits in high-risk breast cancer and Keytruda combo results ...

In a report released today, Steve Scala from TD Cowen maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of ...

Shares of AstraZeneca PLC AZN inched up 0.45% to £107.02 Monday, on what proved to be an all-around favorable trading session ...

Trying to break from the decade-old practice of using BTK inhibitors indefinitely to treat blood cancer, AstraZeneca has ...

Updated results from the OlympiA Phase 3 trial showed AstraZeneca (AZN) and Merck’s (MRK) Lynparza demonstrated sustained, clinically ...

AstraZeneca (AZN) and Merck (MRK) reported positive long-term survival data for their drug Lynparza in the treatment of ...

The breast cancer drug Enhertu will be added to China’s national health insurance scheme beginning in the new year — despite ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.